Skip to main content
SpringerLink
Log in

Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

  1. Suzuki S, Yamashita T, Akao M, Okumura K and J-ELD (2020) AF Investigators. Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis. Eur J Clin Pharmacol 76:1111–1124.

  2. Okumura K, Yamashita T, Suzuki S, Akao M and J-ELD (2020) AF Investigators. A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry). Clin Cardiol 43:251–259.

  3. Akao M, Yamashita T, Okumura K and J-ELD (2016) AF Investigators. Study design of J-ELD AF: a multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients. J Cardiol 68:554–558.

Download references

Acknowledgements

We would like to thank the J-ELD AF investigators for their support in patient registration and data collection in the main study used in this sub-cohort analysis. This study was conducted by the Cardiovascular Institute Academic Organization (CVI ARO), Tokyo, Japan, subsidized and funded by pharmaceutical and medical device companies.

Funding

Bristol-Myers Squibb K.K. provided monetary support for this study. This study was partially supported by the Practical Research Project for Life-Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus from Japan Agency for Medical Research and Development, AMED (15656344 and JP17ek0210082). However, there was no conflict of interest between the study center and sponsor concerning the conduct of the study or study outcomes.

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-ku, Tokyo, 106-0031, Japan

    Shinya Suzuki & Takeshi Yamashita

  2. Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

    Masaharu Akao

  3. Division of Cardiology Saiseikai, Kumamoto Hospita, Kumamoto, Japan

    Ken Okumura

Authors
  1. Shinya Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaharu Akao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ken Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Contributions by each author according to the Contributor Roles Taxonomy (CRediT):

SS: conceptualization, data curation, formal analysis, investigation, methodology, writing—original draft;

TY: conceptualization, funding acquisition, investigation, methodology, project administration, supervision, writing—review and editing;

MA: conceptualization, investigation, project administration, writing—review and editing;

KO: conceptualization, funding acquisition, investigation, project administration, supervision, writing—review and editing

Corresponding author

Correspondence to Shinya Suzuki.

Ethics declarations

Compliance with ethical standards

Prior to the start of the main study, the investigators in charge received a review from the ethics committee of their main participating facility and acquired approval. Prior to enrollment, the contents of the study were explained to the patients using explanatory documents and consent documents, and written consent was obtained. If a patient withdrew consent during the observation period, all existing data collected from the patient were discarded. The study plan and its design were registered in the UMIN Clinical Trials Registry (UMIN000017895).

Conflict of interest

SS received research funding from Daiichi-Sankyo and Mitsubishi-Tanabe. TY received lecture fees from Bristol Myers Squibb, Daiichi-Sankyo, Bayer, Pfizer, Ono Pharmaceutical, and Toa Eiyo, and research funding from Bayer and Daiichi Sankyo. MA received lecture fees from Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Bayer Healthcare, and Daiichi-Sankyo. KO received lecture fees from Daiichi-Sankyo, Boehringer Ingelheim, and Johnson and Johnson.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 24.1 mb)

Supplementary file2 (PDF 191.7 mb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suzuki, S., Yamashita, T., Akao, M. et al. Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban. Eur J Clin Pharmacol 77, 1757–1758 (2021). https://doi.org/10.1007/s00228-021-03135-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-021-03135-8

Search

Navigation